每经记者｜陈星 每经编辑｜张海妮 9月22日早间，新里程（002219.SZ，股价2.34元，市值79.26亿元）公告，公司董事长林杨林解除留置措施。公告显示，林杨林已能正常履行董事长职责，公 司生产经营情况正常。 今年7月初，公司公告，林杨林被太原市小店区监察委员会实施留置并立案调查，公司确认所涉事项与公司无关。新里程2024年年报显示，林杨林2024年度 从公司获得的薪酬为3.68万元（税前），期末持有公司股份2600万股。 在7月初的公告中，新里程曾表示，本事项（董事长林杨林被实施留置并立案调查）预计不会对公司生产经营造成实质性重大不利影响。公司尚未知悉本事 项的进展及明确结论，公司将持续关注上述事项的后续情况，并严格按照有关法律、法规的规定和要求，及时履行信息披露义务。 公开资料显示，林杨林生于1981年，对外经济贸易大学硕士研究生，曾任北大医疗产业基金管理有限公司CEO（首席执行官）；现任新里程健康集团有限公 司CEO、北京新里程健康产业集团有限公司董事长、新里程健康科技集团股份有限公司董事长等职务。 新里程2024年年报显示，林杨林于2021年3月29日开始出任公司董事长。 《每日经济新闻》记者注 ...

Group 1: Financial Performance - In 2024, the company reported a revenue of 2.971 billion yuan, a decrease of 18.06% year-on-year, and a net loss of 1.329 billion yuan, with a decline of 2920.55% [32] - The net cash flow from operating activities in 2024 was -149.8 million yuan, an improvement of 39.87% compared to -249 million yuan in the previous year [11] - In Q1 2025, the company achieved total revenue of 755 million yuan, a decrease of 3.53% year-on-year, while the net profit attributable to shareholders was 1.1572 million yuan, down 94.99% [14] Group 2: Market Strategy and Product Development - The company plans to enhance its market presence by focusing on product innovation, efficiency improvement, and structural optimization to achieve sustainable development [12] - In 2024, the company launched new products such as hair growth capsules and white blood cell-enhancing granules, with plans for continued expansion in 2025 [12] - The company aims to improve its market share for core products, including the compound Ku Shen injection and Minoxidil lotion, which has a market share of 47.3% [25] Group 3: Response to Industry Challenges - The company is adapting to industry challenges such as centralized procurement and medical insurance cost control by optimizing its product structure and focusing on high-value drugs [10] - The company has implemented measures to improve cash flow, including better management of accounts receivable and reducing long payment terms in wholesale business [11] - The company is continuously monitoring market dynamics and adjusting strategies to ensure stable growth despite external pressures [15] Group 4: R&D and Innovation - In 2024, the company invested 251 million yuan in R&D, a year-on-year increase of 25.27%, focusing on innovative drugs and modern traditional Chinese medicine [18] - The company has established a new drug creation center in Shanghai and initiated clinical research for new anti-tumor drugs [18] - The company is committed to enhancing its R&D capabilities and has made significant progress in various projects, including the registration of traditional Chinese medicine with the FDA [18] Group 5: Corporate Governance and Investor Relations - The company is implementing a share repurchase plan, having repurchased 51.025 million yuan worth of shares by April 30, 2025, which will be included in the cash dividend calculation [4] - The company emphasizes transparency and will disclose any significant developments regarding acquisitions and financial management in accordance with legal requirements [12] - The company acknowledges investor concerns regarding stock performance and is focused on improving operational efficiency and communication with the market [3]

Group 1 - The core viewpoint of the news is that Shanxi Zhendong Pharmaceutical Co., Ltd. reported significant financial growth in 2024, achieving an operating income of 2.971 billion yuan and a turnaround in profit for Q1 2025 with a net profit of 28,960 yuan, marking a year-on-year increase of 103.37% [1] - In 2024, the company's key products, including Yanshu Compound Sophora Injection and Dafeixin Minoxidil Lotion, maintained steady growth, with the former leading in usage among similar drugs for three consecutive years and the latter achieving a market share of 47.3% [1] - The company expanded its product offerings in 2024 with new selections in the centralized procurement process, including Du Yi Wei Granules and Dengzhanhua Dispersible Tablets, which are expected to significantly boost sales in grassroots markets [1] Group 2 - In the innovative drug sector, the company completed the efficacy evaluation of a new skin drug and initiated clinical trials for an innovative traditional Chinese medicine, ZD16, while also starting preclinical research for an anti-tumor new drug [2] - The company is advancing 30 raw material drug projects and 31 formulation projects, including the FDA registration of Yanshu and research on its efficacy for pancreatic cancer [2] - A collaboration was signed with Westlake University and Beijing Natural Intelligence Pharmaceutical Technology Co., Ltd. to modernize the research and development of traditional Chinese medicine using AI technology [2]